Prognostic factors of alveolar rhabdomyosarcoma in childhood. An international society of pediatric oncology study

• Published in: Cancer 1991-08, Vol.68 (3), p.493-498
• Main Authors: Reboul‐Marty, J., Mosseri, V., Asselain, B., Quintana, E., Zucker, J. M., Flamant, F., Rodary, C.
• Format: Article
• Language: English
• Subjects: Adolescent; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Staging; Pediatrics; Prognosis; Rhabdomyosarcoma - drug therapy; Rhabdomyosarcoma - mortality; Rhabdomyosarcoma - pathology; Survival Analysis
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/1097-0142(19910801)68:3<493::AID-CNCR2820680308>3.0.CO;2-#

Pretreatment characteristics of 57 patients with alveolar rhabdomyosarcoma (RMS) registered by the International Society of Pediatric Oncology (SIOP) between January 1975 and December 1983 were identified to perform a prognostic factor study. Living status and disease‐free survival (DFS) time were assessed for all patients on January 1, 1988. By multi‐variate analyses, lymph node involvement (P = 0.0003) and tumor invasiveness (P = 0.007) were identified as the most significant covariates correlated with survival. A model including N stage (P = 0.001) and age (P = 0.03) was selected for predicting DFS rates. Children between 5 and 10 years of age had better DFS rates than those younger than 5 years of age or those older than 10 years of age. The authors suggest a prognostic classification that could allow treatment to be adjusted according to clinical staging.